Troglitazone (CS-045): A new antidiabetic agent

Hormone and Metabolic Research

Volumn 29, Issue 5, 1997, Pages 203-213

  Kaneko, T ^a  

^a YAMAGUCHI ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; ENGLITAZONE; PIOGLITAZONE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG EFFECT; DRUG METABOLISM; GLUCOSE UTILIZATION; HORMONE RESPONSE; INSULIN RESISTANCE; INSULIN TREATMENT; LIVER METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

ANIMALIA;

EID: 0030835763     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979023     Document Type: Review

References (81)

1. DeFronzo RA, Ferrannini E: Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194 (1991).
2. Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595-1607 (1988).
3. Fujita T, Sugiyama Y, Taketomi S, Shoda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methylcyclohexylmethoxy)-benzyl]-thazolidine-2,4-dione (ADD-3870, U63287, ciglitazone), a new antidiabetic agent. Diabees 32: 804-810 (1983).
4. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045. Diabetes 37: 1549-1557 (1988).
5. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, Sasahara K: Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 46: 1-57 (1994).
6. Kawai K, Tokui T, Muramatsu S, Okada T, Ishigami M, Komai T: Enterohepatic circulation of sulfate and glucuronide conjugate of CS-045, an antidiabetic drug. Xenobio Metabol Dispos 6 (Suppl): 109 (1991).
7. 14C-labelled CS-045). J Labelled Compd Radiopharm XXVIII: 911-920 (1990).
8. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57 BL/KsJ-db/db mice. Metabolism 40: 1213-1218 (1991).
9. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatani K, Sasaki H: Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocrine Journal 40: 343-349 (1993).
10. Fujiwara T, A Okuno, S Yoshioka, H Horikoshi: Suppression of hepstic gluconeogenesis in long-term troglitazone treated diabetic KK and C57 BL/KsJ-db/db mice. Metab 44: 486-490 (1995)
11. Blackmore PF, McPherson RK, Stevenson RW: Action of the novel antidiabetic agent englitazone in rat hepatocytes. Metabolism 42: 1583-1587 (1993).
12. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39: 1056-1062 (1990).
13. Murano K, Inoue Y, Emoto M, Kaku K, Kaneko T: CS-045, a new oral antidiabetic agent, stimulates frutose-2,6-bisphosphate production in rat hepatocytes. European J Pharmacology 254: 257-262 (1994).
14. Hofmann CA, Edward III CW, Hillman RM, Colca JR: Treatment of insulin resistant mice with the oral antidiabetic agent pioglitazone; evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 130: 735-740 (1992).
15. Okuno A, Shiota M, Fujiwara T, Yoshioka S, Sugano T, Horikoshi H: Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb (unpublished data and cited from Troglitazone CS-045), A new antidiabeti drug by Horikoshi H et al. Annu Rep Sankyo Res Lab 46: 1-57 (1994).
16. Kawaguchi M, Tanigawa K, Kato Y: A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rat. Endocrine J 42: 557-561 (1995).
17. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42: 75-80 (1993).
18. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertention 8: 316-320 (1995).
19. Sankyo Report on CS-045, 1994 (in Japanese).
20. Nagasaka Y, Kaku K, Nakamura K, Kaneko T: The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol 50: 1109-1111 (1995).
21. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H: Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32: 421-428 (1989).
22. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of troglitazone on calcium channels in vascular smooth muscle. Hypertension 24: 170-175 (1994).
23. Walsh MF, Barage M, Syed A, Igwe R, Zhang F, Sowers JR: Troglitazin einduced both immediate and delayed relaxation in rat tail arteries (abstract). Proc Int COngress Endo 2: 969 (1996).
24. Ren J, Dominiques L, Sowers JR, Davidoff AJ: Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventircular myocytes. Diabetes 12: 1822-1825 (1996).
25. Kimura K, Tozuka S, Mori M: The acute toxicity studies of CS-045 in mice, rats and cynomolgus monkeys. J Clin Ther Med 9 (Suppl 3): 217-225 (1993).
26. Matsunuma N, Kimura K, Yamashita K, Miyakoshi S, Manabe: Chronic toxicity study on CS-045 in rat treated orally for 1 year. J Clin Ther Med 9 (Suppl 3): 299-315 (1993).
27. Mayfield R, McLean T, Crook D, Buist DP, Gopinath C: CS-045 toxicity to cynomolgus monkeys by repeated oral administration for 52 weeks. J Clin Ther Med 9 (Supl 3): 317-341 (1993).
28. Hirano K, Hagiwara T, Umezawa T, Uchida T, Watanabe M, Matsushima H: Mutagenicity studies of CS-045 in bacteria, in mammalian tissue culture cells and in mice. J Clin Ther Med 9 (Suppl 3): 375-388 (1993).
29. Shinkai K, Kimura T, Ishikawa N, Kurita Y, Muramatsu K: Antigenicity studies on CS-045 in guinea pigs and mice. J Clin Ther Med 9 (Suppl 3): 363-373 (1993).
30. Kobayashi M, Iwasaki M, Ohgaku S, Maegawa H, Watanabe N, Shigeta Y: A new potentiator of insulin action: postreceptor activation in vitro. FEBS Lett 163: 50-53 (1983).
31. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41: 476-483 (1992).
32. Lee MK, Miles PDG, Khoursheed M, Gao KM, Mossa AR: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439 (1994).
33. Yagi N, Takasu N, Higa S, Ishikawa K, Murakami K, Mimura G: Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. Horm Metab Res 27: 439-441 (1995).
34. McPherson RK, Gibbs EM, Treadway JL, Stevenson RW: Englitazone effects on signal transduction and metabolic responses to insulin and glucagon in isolated rat hepatocytes. Diabetes 42 (Suppl 1): 36A (1993).
35. y mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 267: E95-E101 (1994).
36. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Itabashi A, Ishii J: Effect of troglitazone (CS-45) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism 44: 1626-1630 (1995).
37. Maegawa H, Ide R, Hasegawa M, Katsuya U, Egawa K, Iwanishi M, Kikkukawa R, Shigeta Y, Kashiwagi A: Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J Biol Chem 270: 7724-7730 (1995).
38. Ciaraldi TP, Abrams L, Chung J, Henry RR: Glucose transport in cultured human skeletal muscle cells of control and NIDDM subjects: regulation by inslin and pioglitazone. Clin Res 42: 26A (1994).
39. Gibbs EM, Banker MJ, McCoid SC, Genereux PE, Pereira DA: Differential regulation of GLUT1 and GLUT4 mRNA by the antidiabetic agent englitazone. Diabetes 41 (Suppl 1): 202A (1992).
40. Steavenson RW, McPherson RK, Persson LM, Genereux PE, Kreutter DK, Gibbs EM: The new antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high fat diet. Diabetes 40 (Suppl 1): 337A (1991).
41. McCall JL, Tuckey JA, Parry BR: Serum tumor necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg 79: 1361-1363 (1992).
42. Offner F, Philippe J, Vogeares D, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Lerous-Roels G: Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 116: 100-105 (1990).
43. Old LJ: Tumor necrosis factor (TNF). Science 230: 630-632 (1985).
44. Shangraw RE, Jahoor F, Miyoshi H, Neff WA, Stuart CA, Herndon DN, Wolfe RR: Differentiation between septic and postburn insulin resistance. Metabolism 38: 983-989 (1989).
45. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impaires insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43-52 (1992).
46. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-90 (1993).
47. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS: Altered gene expression of tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270 (1994).
48. Szalkowski D, White-Carrington S, Berger J, Zhang B: Antidiabetic thiazolidinedione blocks the inhibitory effect of tumor necrosis factor α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-1481 (1995).
49. Cornelius P, MacDonald OA, Lane MD: Regulation of adipocyte development. Annu Rev Nutr 14: 99-129 (1994).
50. Chawla A, Schwwarz EJ, Dimaculangen DD, Lazar MA: Peroxisome proliferator-activated receptor (PPAR): adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800 (1994).
51. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman M: mPPAR 2: tissue-specific regulator of an adipocyte enhancer. Gene and Development 8: 1224-1234 (1994).
52. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: Control of the peroxisomal oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887 (1992).
53. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650 (1990).
54. Kliewer SA, Formen BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-ctivated receptors. Proc Natl Acad Sci USA 91: 7355-7359 (1994).
55. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adepogenesis in fibroblasts by PPAR 2, a lipid-activated transcription factor. Cell 79: 1147-1156 (1994).
56. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkins WO, Willson TM, Kliewer SA: An antidiabetic thiazolizinedione is a high affinity ligand for peroxisome proliferator-activated receptor - (PPAR). J Biol Chem 270: 12953-12956 (1995).
57. Wilson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and antihyperglycemic activity of thiazolidinedione. J Med Chem 39: 665-668 (1996).
58. Braissant O, Foufelle F, Scott C, Dauce M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β and γ in the adult rats. Endocrinology 137: 354-366 (1996).
59. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest 97: 2553-2561 (1996).
60. Jones PD, Savory R, Borra HP, Bell AR, Gray TJB, Jenkins NA, Gilbert DJ, Copeland NC, Bell DR: Chromosomal localization, inducibility, tissue specific expression and strain differences in three murine peroxisome proliferator-activated receptor genes. Eur J Biochem 233: 219-226 (1995).
61. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669 (1996).
62. Shibata H, Nu S, Kobayshi M, Izumu T, Maeda E, Sasahara K, Yamaguchi K, Morita A, Nishiwaki A: Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers - Safety and pharmacokinetics in single administration. J Clin Ther Med 9: 1503-1518 (1993).
63. Shibata H, Nii S, Kobayashi M, Izumu T, Maeda E, Sasahara K, Yamaguchi K, Morita A, Nishiwaki A: Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers - Safety and pharmacokinetics in repeated administration. J Clin Ther Med 9: 1519-1537 (1993).
64. Kuzuya T, Kosaka K, Takebe K, Iwamoto Y, Yamanouchi S, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: An early phase II clinical trial of a new oral hypoglycemic drug, CS-045, in patients with non-insulin dependent diabetes mellitus. J Clin Ther Med 9: 3-18 (1993).
65. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone - A dose-finding study by dose increasing method. J Clin Ther Med 9: 19-37 (1993).
66. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulfonylureas - A dose-finding study by dose increasing method. J Clin Ther Med 9: 39-60 (1993).
67. Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone - A double-blind, placebo-controlled study. J Clin Ther Med 9: 61-93 (1993).
68. Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic drug Cs-045 in patient with non-insulin dependent diabetes mellitus poorly controlled by sulfonylureas - A double-blind, placebo-controlled study. J Clin Ther Med 9: 95-126 (1993).
69. Akanuma Y, Kosaka K, Kuzuya T, Shigeta Y, Kaneko T: Long-term study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. J Clin Ther Med 9: 127-149 (1993).
70. Ikeda Y, Hamada H, Ohno M, Tajima N, Sakamoto Y: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with obese non-insulin dependent diabetes mellitus. J Clin Ther Med 9: 179-190 (1993).
71. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14: 1083-1086 (1991).
72. Nakano K, Yasuda T, Kitagawa Y, Nakamura N, Kondo M, Kanatsuna T, Mori H, Masaki K, Wada S, Kobayashi Y, Mizuno T, Hasegawa G: Clinical evaluation o fa new oral hypoglycemic drug, CS-045, on daily profile of blood glucose in patients with non-insulin dependent diabetes mellitus. J Clin Ther Med 9: 151-164 (1993).
73. Yamada N, Akanuma Y, Murase T, Kikuchi M, Yamanouchi T, Miyazaki S, Kawazu S, Iwamoto Y, Kawakami M: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus accompanying hypertriglyceridemia. J Clin Ther Med 9: 165-178 (1993).
74. Suter SL, Nolan JJ, Wallace P, Gumbine B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203 (1992).
75. Nolan JJ, Ludvik, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 331: 1188-1193 (1994).
76. Valiquett T, Balagtas C, Whitcomb R: Troglitazone dose-response study in patiets with NIDDM. Diabetes 44 (SUppl 1) abst. 584 (1995).
77. Ghazzi M, Balagtas C, Perez J, Whitcomb R: Treatment of NIDDM patients with troglitazone is not associated with increased cardiac mass or impaired cardiac function, 55th Annual Meeting of the American Diabetes Association 574 (1995).
78. Miyamoto K, Hase K, Taketani Y, Minami H, Oka T, Nakabou Y, Hagihara H: Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun 181: 1110-1117 (1991).
79. Westergaard H: Insulin modulates rat intestinal glucose transporter: effect of hypoinsulinemia and hyperinsulinemia. Am J Physiol 256: G911-G918 (1989).
80. Kosaka K, Hagura R, Kuzuya T: Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 26: 944-952 (1977).
81. Hara H, Egusa G, Yamakido M, Kawate R: The high prevalence of dibetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract 24 (Suppl): S37-S42 (1994).